Copanlisib in the treatment of non-Hodgkin lymphoma

Future Oncol. 2020 Sep;16(26):1947-1955. doi: 10.2217/fon-2020-0195. Epub 2020 Jul 13.


B-cell receptor signaling is important in the pathogenesis of non-Hodgkin lymphoma. The PI3K pathway is activated by B-cell receptor signaling. Recently, several PI3K inhibitors have been in development for the treatment of indolent non-Hodgkin lymphomas. Copanlisib is a PI3Kα and PI3Kδ inhibitor that has been approved for its use as third-line therapy in the treatment of relapsed or refractory follicular lymphoma. The two other PI3k inhibitors approved by the US FDA in this setting are idelalisib and duvelisib. In this review, we compare the efficacy and adverse event profile of these different PI3K inhibitors and discuss the advantages and challenges of using copanlisib along with a guide on managing routinely encountered adverse events in the clinics.

Keywords: PI3K inhibitor therapy; copanlisib; lymphoma; targeted therapy.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Clinical Trials as Topic
  • Disease Management
  • Disease Susceptibility
  • Humans
  • Hyperglycemia / etiology
  • Hyperglycemia / therapy
  • Hypertension / etiology
  • Hypertension / therapy
  • Lymphoma, Non-Hodgkin / diagnosis
  • Lymphoma, Non-Hodgkin / drug therapy*
  • Lymphoma, Non-Hodgkin / etiology
  • Lymphoma, Non-Hodgkin / mortality
  • Molecular Targeted Therapy*
  • Phosphatidylinositol 3-Kinase / metabolism
  • Phosphoinositide-3 Kinase Inhibitors / pharmacology
  • Phosphoinositide-3 Kinase Inhibitors / therapeutic use*
  • Prognosis
  • Pyrimidines / pharmacology
  • Pyrimidines / therapeutic use*
  • Quinazolines / pharmacology
  • Quinazolines / therapeutic use*
  • Signal Transduction / drug effects
  • Treatment Outcome


  • Biomarkers
  • Phosphoinositide-3 Kinase Inhibitors
  • Pyrimidines
  • Quinazolines
  • Phosphatidylinositol 3-Kinase
  • copanlisib